Axogen Business Summary

Axogen, Inc. (AXGN) is a medical technology leader specializing in the science, development, and commercialization of proprietary surgical solutions for peripheral nerve regeneration and repair. The company generates revenue through the transactional sale of human tissue allografts and synthetic medical devices to hospitals and surgical centers. Its primary business segments are categorized by clinical application: Extremities (trauma and hand surgery), Oral & Maxillofacial (OMF-Head & Neck), and Breast Reconstruction (via its Resensation® technique). The product portfolio is anchored by the Avance® Nerve Graft—the first and only off-the-shelf processed human nerve allograft—complemented by the Axoguard® line of connectors, protectors, and caps. Axogen maintains a dominant position in the niche peripheral nerve market with 2025 revenues reaching approximately $225.2 million and gross margins exceeding 74%. It competes directly with diversified medical device giants such as Stryker, Integra LifeSciences, Baxter International, and Medtronic, distinguishing itself through its specialized focus on the peripheral nerve surgical algorithm and its recent FDA Biologics License Application (BLA) approval for Avance®. Founded in 2002 by Jamie Grooms and John P. Engels, Axogen originated as a spin-off from the University of Florida based on the foundational research of neuroscientist David Muir, Ph.D. The current leadership team is headed by President and CEO Michael Dale, who assumed the role in August 2024 following a 30-year career leading high-growth medical technology firms like GI Dynamics and HeartWare. The executive suite includes CFO Lindsey Hartley, Chief Innovation Officer Erick DeVinney, and Chief Medical Officer Dr. Ivica Ducic, a renowned peripheral nerve surgeon. The company is governed by a board chaired by Paul G. Thomas and includes Lead Director Amy Wendell, a former senior executive at Covidien. Axogen is characterized by high institutional backing, with major stakeholders including BlackRock and Vanguard, reflecting its transition from a venture-backed startup to a established public entity on the NASDAQ.